Salesforce Stock's Sell-Off Keeps Getting Worse. Is It Finally Time to Buy the Stock?

Salesforce reported fiscal Q1 2027 revenue of $11.1 billion, up 13% year over year, with AI and data ARR reaching $3.4 billion, up about 200%, and Agentforce surpassing $1 billion in ARR. The company posted a record 34.8% adjusted operating margin, generated $6.6 billion in free cash flow, and returned $27.5 billion to shareholders via buybacks, but management still flagged weakness in commerce and Tableau and expects organic growth to reaccelerate later this year. Despite these fundamentals, the stock is down about 40% year to date and now trades near 12x forward earnings amid AI disruption fears.

Analysis

The market is pricing CRM as if AI is a substitution shock, but the harder read is that AI is currently widening the product surface area and monetization optionality. If agents increase automation inside workflows, the near-term winner is not necessarily a lower seat count; it is the vendor that can charge both for the human workflow and the agent execution layer, which is exactly where CRM is trying to move its pricing model. That creates a second-order benefit for platform incumbents with distribution and data, while point-solution AI vendors face a tougher path to durable pricing power.

The real tell is not revenue growth, but the combination of ARR expansion, record margin, and aggressive repurchases. With the stock at a compressed multiple, buybacks become a larger driver of EPS than incremental top-line acceleration, so the equity can work even if organic growth stays mid/high-single digits for several quarters. That setup is particularly powerful if management’s back-half reacceleration lands, because the market is currently paying almost no premium for that optionality.

The main risk is not next quarter’s numbers; it is a multi-year repricing of software economics if customers conclude they can buy fewer seats and more usage-based automation. That would cap terminal multiples across enterprise software, even for execution-heavy names, and explains why the stock can stay cheap longer than fundamentals would suggest. A cleaner read is that the selloff is probably overdone versus the current quarter, but not necessarily against a three-year AI disruption horizon.

Competition-wise, INFA likely benefits as CRM leans more heavily on data infrastructure and integration depth, while weaker adjacent modules such as commerce and analytics remain vulnerable to tighter budget scrutiny. If CRM successfully converts AI usage into metered revenue, the real losers are less efficient SaaS vendors with weaker embedded data moats and no ability to offset seat pressure with consumption-based pricing.

Key Decisions for Investors

• Initiate a small CRM starter long now; add only on weakness if the stock holds the low-valuation regime and management confirms back-half organic reacceleration. Risk/reward is favorable for a 6-12 month mean reversion, but cap sizing because the AI disruption overhang can re-rate the multiple for years.
• Buy CRM Jan-2027 call spreads instead of outright shares to express upside from multiple normalization and buyback-driven EPS support. This limits downside if the market continues to assign a structural discount to software.
• Use CRM weakness as a relative long versus lower-quality enterprise software names with weaker data moats; a CRM/peer long-short basket is preferable to an index long because the winner should be the platform that can monetize both seats and usage.
• Keep INFA on a watchlist as a secondary beneficiary of CRM’s AI/data buildout; if CRM’s AI monetization persists, integration and data-layer demand should stay resilient over the next 2-4 quarters.
• Avoid chasing the rebound until the market sees one more quarter of seat growth plus sustained AI ARR acceleration; without that confirmation, the stock can remain a value trap despite cheap headline multiples.